definiens: fJduet Ie } ' Gauc/,eJ ' Disease " shall mean 0 ) both ( A ) the completion of the End of Phase II Meeting with the FDA and receipt of scientific advice from the EMEA 's Committee for Medicinal Products for Human Use ( " CHAfP ' ) with respect to such Licensed Product and ( B ) the determination by the JSC to initiate a Phase III Clinical Trial for such Licensed Product for Gaucher disease or ( ii ) initiation of a Phase III Clinical Trial for Gaucher disease approved by [COMPANY] at the JSC not involving Section 16.8.1(b ) ( d ) . } < [ * * * J. > ( b ) { shall mean ( 1 ) both ( a ) the completion of the End of Phase II Meeting with the FDA and receipt of scientific advice from the CHMP ... vith respect to such Licensed Product and ( b ) the determination by the JSC to initiate a Phase III Clinical Trial fur such Licensed Product fur Pompe Disease or ( 2 ) initiation of a Phase III Clinical Trial for Pompe disease approved by [COMPANY] at the JSC not involving Section 16.8.1(b ) ( d ) . } < [ * * * J. > 1 * * * ] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED, ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED